About
Eye-drop Treatment
Areas of Focus
Categories
Small Molecule PharmaceuticalMiddle East
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
1,029
By Phase
PHASE3: 3PHASE2: 3
By Status
COMPLETED: 6
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
Today
Hover over trial bars to see details
Recent Trials
NCT05393895Lead Sponsor
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
PHASE3Completed
178 participants
Started: Apr 22, 2022 · Completed: Dec 1, 2022
NCT04599972Lead Sponsor
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
PHASE3Completed
304 participants
Started: Oct 26, 2020 · Completed: Jan 28, 2022
NCT04599933Lead Sponsor
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)
PHASE3Completed
309 participants
Started: Oct 18, 2020 · Completed: Feb 19, 2022
NCT03885011Lead Sponsor
A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia
PHASE2Completed
166 participants
Started: Feb 26, 2019 · Completed: Jul 26, 2019
NCT02965664Lead Sponsor
Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
PHASE2Completed
36 participants
Started: Dec 31, 2016 · Completed: Apr 30, 2017
Locations (1)
Headquarters
Herzliya, Israel
Map
Loading map...